PharmaPoint: Macular Edema and Macular Degeneration - US Drug Forecast and Market Analysis to 2023

Description:

PharmaPoint: Macular Edema and Macular Degeneration - US Drug Forecast and Market Analysis to 2023

Summary

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

The corticosteroid implants Ozurdex and Iluvien are also anticipated to enter the US DME market during the forecast period, with Ozurdex receiving FDA approval as a DME treatment in June 2014, and Iluvien expected to launch in Q1 2015 following it's approval in September 2014. This new class of drugs is expected to be a significant driver of growth in the overall ME market, and by the end of the forecast period in 2023.

Scope

- Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Macular Edema and Macular Degeneration market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Related Reports
3 Disease Overview
3.1 Macular Degeneration Overview
3.1.1 Etiology and Pathophysiology
3.1.2 Classification
3.1.3 Symptoms and Diagnosis
3.2 Macular Edema Overview
3.2.1 Etiology and Pathophysiology
3.2.2 Classification
3.2.3 Symptoms and Diagnosis
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Macular Edema Diagnosis
4.1.2 Macular Degeneration Diagnosis
4.1.3 Treatment Guidelines and Leading Prescribed Drugs
4.1.4 Clinical Practice
4.2 US
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands
5.2.1 Lucentis (ranibizumab)
5.2.2 Eylea (aflibercept)
5.2.3 Avastin (bevacizumab)
5.2.4 Macugen (pegaptanib sodium)
5.2.5 Visudyne (verteporfin)
5.2.6 Corticosteroid Implants
6 Unmet Need and Opportunity
6.1 Overview
6.2 Treatment for Dry AMD
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Longer-Acting Anti-VEGF Drug Therapy
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Less Invasive Drug Formulations
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Awareness and Earlier Patient Diagnosis
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Home Monitoring of AMD Progression
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Abicipar pegol
7.2.2 Fovista
7.2.3 Squalamine
7.2.4 Lampalizumab
7.2.5 Emixustat
7.2.6 Optina
7.3 Promising Drugs in Early-Stage Development
7.3.1 Complement Inhibitors
7.4 Other Drugs in Development
7.5 Biosimilars
8 Market Outlook
8.1 US
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers - Global Issues
8.1.4 US - Drivers and Barriers
1.2 List of Figures

Figure 1: Anatomy of the Eye and Macula
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
Figure 3: Color Fundus Photographs of Dry and Wet AMD
Figure 4: FAF Imaging of GA
Figure 5: Imaging of wAMD
Figure 6: CMT in DME
Figure 7: RVOs (BRVO and CRVO) on an FA
Figure 8: Increased CRT in ME-RVO
Figure 9: ME Clinical Treatment Flowchart
Figure 10: AMD Clinical Treatment Flowchart
Figure 11: Eylea's Clinical Development in DME and ME-BRVO
Figure 12: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME
Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
Figure 14: Abicipar Pegol's Clinical Development in wAMD and DME
Figure 15: Clinical and Commercial Positioning of abicipar pegol
Figure 16: Fovista's Clinical Development in wAMD
Figure 17: Clinical and Commercial Positioning of Fovista
Figure 18: Squalamine's Clinical Development in wAMD and DME
Figure 19: Clinical and Commercial Positioning of squalamine
Figure 20: Lampalizumab's Development in wAMD
Figure 21: Clinical and Commercial Positioning of lampalizumab
Figure 22: Emixustat Clinical Development in dAMD
Figure 23: Clinical and Commercial Positioning of emixustat
Figure 24: Optina's Clinical Development in DME
Figure 25: Clinical and Commercial Positioning of Optina
Figure 26: Individual Drug Sales for ME in the US, 2013-2023
Figure 27: Individual Drug Sales for AMD in the US, 2013-2023

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3128280/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | PharmaPoint: Macular Edema and Macular Degeneration - US Drug Forecast and Market Analysis to 2023 |
| Web Address: | http://www.researchandmarkets.com/reports/3128280/ |
| Office Code: | SC |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ( )</th>
<th>Mrs ( )</th>
<th>Dr ( )</th>
<th>Miss ( )</th>
<th>Ms ( )</th>
<th>Prof ( )</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp